ClinicalTrials.gg
CompletedNCT01469000Updated Sep 10, 2019Results posted

A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC)

A Phase 2 interventional study of Gefitinib and Pemetrexed in Carcinoma, Non Small Cell Lung, sponsored by Eli Lilly and Company. Completed at 25 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-10.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
195
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung — 21 open to participants now, 32 under way, 11 of them phase 3. Pemetrexed · Carcinoma, Non-Small-Cell Lung.

Enrollment
53rd of 223
195 · median 64
Started
2012
with 8 others
Phase 2
128 of 227
12 open now
Registered
116th of 227
by date
Lead sponsor
40 of 227
Eli Lilly and Company

Among the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, this one is the 53rd largest by enrollment of the 223 interventional ones that give a count, is one of 9 that started in 2012, is one of 128 in phase 2, and was the 116th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

21 of the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About pemetrexed

Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The purpose of this study is to compare the combination of pemetrexed and gefitinib versus gefitinib alone, in terms of progression-free survival. This study is in participants who have stage IV non squamous NSCLC with activating epidermal growth factor mutations and who have not had any previous chemotherapy for stage IV disease.

03

Conditions studied

  • Carcinoma, Non Small Cell Lung
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed advanced (Stage IV) or recurrent non-squamous NSCLC
  • Eligible participants of must agree to use adequate methods during the study period and for at least 6 months after the last dose of study therapy
  • Negative pregnancy test for women of
  • Males or females, aged 18 years or above
  • (ECOG) Performance Status 0-1
  • The participant's primary NSCLC tumor has an activating Epidermal Growth Factor Receptor (EGFR) mutation, as determined by any validated method
  • The participant consents to provide a tissue sample for prestudy EGFR mutation testing and the tumor tissue sample is available for detection of EGFR expression and other markers for centralized testing by Lilly
  • The participant has at the time of study entry, documented by computed tomography (CT) scan or magnetic resonance imaging (MRI), as defined by the (RECIST) version 1.1
  • The participant has not had any prior systemic chemotherapy, immunotherapy, or biological therapy (for example, targeted therapy, such as erlotinib or gefitinib) for Stage IV or recurrent non-squamous NSCLC
  • The participant has adequate organ function, defined as:

    • White blood cell count ≥3 x 10\^9/liter (L); (segmented and bands) ≥1.5 x 10\^9/L; count ≥100 x 10\^9/L; ≥9.0 gram per deciliter (g/dL)
    • Total ≤1.5 times the (ULN) range; and alkaline phosphatase (AP), (AST) and alanine transaminase (ALT) ≤2.5 times ULN (or ≤5 times ULN if the liver has tumor involvement)
    • Calculated ≥45 milliliter per minute (mL/min)
  • The participant is able to take folic acid, vitamin B12, and dexamethasone, according to the protocol's requirements
  • of at least 3 months
  • Provision of
  • Prior radiation therapy is allowed to \<25% of the bone marrow; however, prior radiation to the whole pelvis not allowed. Prior radiation therapy must be completed at least 2 weeks prior to first study-drug administration. Participants must have recovered from the acute toxic effects prior to first study-drug administration.

Exclusion criteria

Exclusion Criteria:

  • The participant has received prior chemotherapy for advanced and/or disease, or /neoadjuvant treatment with pemetrexed or an EGFR-tyrosine Kinase inhibitor (TKI)
  • The participant's tumor contains predominantly small cell lung cancer or squamous NSCLC
  • The participant is receiving concurrent treatment with any other anticancer therapy, including other chemotherapy, immunotherapy, hormonal therapy, chemoembolization, biological or targeted therapy, or radiotherapy (palliative irradiation of bone lesions is allowed)
  • The participant has untreated central nervous system (CNS) metastases Participants with treated are eligible if they are clinically stable with regard to neurologic function, off after cranial irradiation (whole brain radiation therapy, focal radiation therapy, stereotactic radiosurgery) ending at least 2 weeks before enrollment, or after surgical resection performed at least 28 days before enrollment. No evidence of Grade ≥1 CNS hemorrhage based on pretreatment MRI or Intravenous (IV) contrast CT scan (performed within 21 days before randomization).
  • The participant has undergone radiotherapy within 28 days before enrollment (localized radiotherapy for pain relief allowed, provided 25% or less of their total bone marrow had been irradiated)
  • The participant has congestive heart failure ( [NYHA] II-IV) or symptomatic or poorly controlled cardiac arrhythmia
  • The participant has a serious illness or medical condition that would compromise their safety or impair their ability to comply with the protocol's requirements, including, but not limited to, the following:

    • Known (HIV) infection or acquired immunodeficiency syndrome (AIDS)-related illness
    • Active or uncontrolled clinically serious infection
    • Previous or concurrent except for basal or squamous cell skin cancer and/or in situ carcinoma of the cervix, or other solid tumors treated curatively and without evidence of recurrence for at least 5 years prior to the study
    • Uncontrolled metabolic disorders or other nonmalignant organ or systemic diseases or secondary effects of cancer that induce a high medical risk and/or make assessment of survival uncertain
    • Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the Investigator would make the participant ineligible for entry into this study
    • The participant has significant third space fluid retention, and is not amenable for required repeated drainage
    • Known allergy or reaction to any of the treatment components
  • Are unable to interrupt aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs), other than an aspirin dose ≤1.3 grams per day, for at least 2 days (5 days for long-acting agents [for example, piroxicam]) before, during, and for at least 2 days after administration of pemetrexed
  • Concomitant use of cytochrome P450 (CYP)3A4 inducers or inhibitors
  • Participants under therapy with warfarin or coumarin derivatives who are unable to switch to low molecular weight heparin, unless regular monitoring of changes in (PT) (PT/international normalized ratio [INR]) will be applicable
  • Any known significant ophthalmologic abnormalities of the surface of the eye. The use of contact lenses is not recommended during the study
  • Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an product or non-approved use of a drug or device, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study Participants participating in surveys or observational studies are eligible to participate in this study
  • The participant has previously received treatment with gefitinib, erlotinib or pemetrexed
  • Any evidence of clinically active interstitial lung disease. Asymptomatic participants with chronic, stable, radiographic changes are eligible.
  • Have preexisting idiopathic pulmonary fibrosis as evidenced by computed tomography (CT) scan/x-ray at baseline; have or had any disease of acute lung injury, idiopathic pulmonary fibrosis, pulmonary pneumonia, or pneumoconiosis evident on an x-ray; have or had any disease of radiation pneumonia or drug-induced pneumonia, which requires treatment with corticosteroids.
  • The participant is pregnant or breastfeeding
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
195 participants (actual)

Study arms

  • Experimental
    250 mg Gefitinib/500 mg Pemetrexed

    250 milligrams (mg) Gefitinib taken orally once daily (QD) and 500 milligrams per square meter (mg/m²) Pemetrexed taken intravenously (IV) once every 3 weeks concurrently with Gefitinib taken orally QD.

    Drug: Gefitinib · Drug: Pemetrexed

  • Active comparator
    250 mg Gefitinib

    250 milligrams (mg) Gefitinib taken orally QD

    Drug: Gefitinib

Interventions

  • 250 mg orally once per day. Number of cycles until disease progression or unacceptable toxicity develops.

    Also known as: Iressa

  • 500 mg/m² IV on day 1 of each 21 day cycle. Number of cycles until disease progression or unacceptable toxicity develops.

    Also known as: Alimta

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    PFS is defined as the time from randomization to the first date of objectively determined progressive disease or death from any cause,whichever is earlier.The censoring is taken in the following order: If a participant didn't have a complete baseline disease assessment,then the PFS time was censored at the enrollment date, regardless of whether or not objectively determined disease progression or death has been observed for the participant;otherwise,if a participant is not known to have died or have objective progression as of the data inclusion cutoff date for the analysis,the PFS time will be censored at the last complete objective progression-free disease assessment date.Progressive disease (PD) was defined as at least a 20% increase in the sum of the diameters of target lesions,taking as reference the smallest sum on study. Also,the sum must also demonstrate an absolute increase of at least 5 millimeter (mm).The appearance of one or more new lesions is also considered progression.

    Time frame: Randomization to Progressive Disease or Death Due to Any Cause (Up to 58.78 Months)

Secondary outcomes

  1. Time To Progressive Disease (TTPD)

    TTPD is defined as time from the date of randomization to the first date of disease progression. For each participant who is not known to have had a progression of disease as of the data-inclusion cut-off date for a particular analysis, or who has died without progression of disease, TTPD will be censored for that analysis at the date of the participant's last tumor assessment prior to that cut-off date. TTPD was analyzed twice: (1) excluding clinical progressions of disease (that is,those not defined according to the RECIST version 1.1 criteria ), and (2) including clinical progressions. Progressive disease (PD) was defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. Also, the sum must also demonstrate an absolute increase of at least 5 millimeter (mm). The appearance of one or more new lesions is also considered progression.

    Time frame: Randomization to Progressive Disease (Up To 58.78 Months)

  2. Overall Survival (OS)

    OS is defined as the time from randomization to the date of death from any cause. Survival time is censored at the date of last contact for participants who are still alive or lost to follow up.

    Time frame: Randomization to Date of Death Due to Any Cause (Up To 67.12 Months)

  3. Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) (Overall Response Rate [ORR])

    ORR is the best response of complete response (CR) or partial response (PR) as classified by the investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). Complete Response (CR) is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Tumor marker results must have normalized. Partial Response (PR) is defined at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters.

    Time frame: Randomization to Progressive Disease (Up to 57.36 Months)

  4. Percentage of Participants With CR, PR, and Stable Disease (SD) (Disease Control Rate [DCR])

    Disease control rate is the percentage of participants with a confirmed CR, PR or SD as classified by the investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST version 1.1) criteria. CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Tumor marker results must have normalized. PR is defined at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters. SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

    Time frame: Randomization to Progressive Disease (Up To 57.36 Months)

  5. Duration of Response (DoR)

    DoR was defined as the time from the date of the first CR or PR to the first date of Progressive Disease (PD) ( RECIST 1.1 Criteria) or death from any cause.CR is the disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \<10 mm.Tumor marker results must have normalized. PR is defined as at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters. PD was defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. Also,the sum must also demonstrate an absolute increase of at least 5 mm.The appearance of one or more new lesions is also considered progression. Participants not known to have died or to have had progression of disease as of the data-inclusion cut-off date for a particular analysis,duration of tumor response was censored at the date of the participants last tumor assessment prior to that cut-off date.

    Time frame: First Observation of CR or PR to Progressive Disease or Death Due to Any Cause (Up To 57.36 Months)

  6. Time to Worsening of Symptom (TWS) as Per Lung Cancer Symptom Scale (LCSS)

    TWS was the elapsed time from the date of randomization to the first date of worsening in any one of the 6 LCSS symptoms. The LCSS (patient and observer) were administered at baseline and at the end of each 21-day cycle, until disease progression, and at short-term follow-up. Content for the patient version -collected using a visual analog scale (VAS) anchored at 0 and 100, respectively representing the best and worst outcome- included 6 disease-specific measures: (appetite, fatigue, cough, dyspnea, hemoptysis and pain) and 3 summary consequences of lung cancer (overall symptom burden, diminished normal activities, and lowered quality-of-life).The observer version included only the 6 disease-specific measures and the responses were collected using a 5-point ordinal scale that was reverse coded with 0 and 100 respectively representing the worst and best outcome.TWS was censored at the date of the last LCSS assessment for participants who were not known to have LCSS worsening.

    Time frame: Baseline to Progressive Disease (Up To 50 Months )

07

Results

Posted Apr 28, 2016

Participant flow

Participant flow — Overall Study
Milestone250 mg Gefitinib/500 mg Pemetrexed250 mg Gefitinib
Started12966
Received at least 1 dose of study drug12665
Completed10962
Not completed204
Withdrew: Withdrawal by subject163
Withdrew: Sponsor decision41

Outcome measures

PrimaryProgression Free Survival (PFS)

PFS is defined as the time from randomization to the first date of objectively determined progressive disease or death from any cause,whichever is earlier.The censoring is taken in the following order: If a participant didn't have a complete baseline disease assessment,then the PFS time was censored at the enrollment date, regardless of whether or not objectively determined disease progression or death has been observed for the participant;otherwise,if a participant is not known to have died or have objective progression as of the data inclusion cutoff date for the analysis,the PFS time will be censored at the last complete objective progression-free disease assessment date.Progressive disease (PD) was defined as at least a 20% increase in the sum of the diameters of target lesions,taking as reference the smallest sum on study. Also,the sum must also demonstrate an absolute increase of at least 5 millimeter (mm).The appearance of one or more new lesions is also considered progression.

Time frame:
Randomization to Progressive Disease or Death Due to Any Cause (Up to 58.78 Months)
Reported as:
Median · Months
Progression Free Survival (PFS)
Months250 mg Gefitinib/500 mg Pemetrexed250 mg Gefitinib
Progression Free Survival (PFS)16.23 (12.58 to 18.73)11.07 (9.66 to 13.83)
Statistical analysis
  • 250 mg Gefitinib/500 mg Pemetrexed vs 250 mg Gefitinib · Regression, Cox · p = 0.009 (1-sided.) · Hazard ratio (hr): 0.67 · 95% CI 0.48 to 0.93Adjusted for gender, performance status, previous adjuvant /neoadjuvant treatment, age, smoking history, mutation type, and country.
SecondaryTime To Progressive Disease (TTPD)

TTPD is defined as time from the date of randomization to the first date of disease progression. For each participant who is not known to have had a progression of disease as of the data-inclusion cut-off date for a particular analysis, or who has died without progression of disease, TTPD will be censored for that analysis at the date of the participant's last tumor assessment prior to that cut-off date. TTPD was analyzed twice: (1) excluding clinical progressions of disease (that is,those not defined according to the RECIST version 1.1 criteria ), and (2) including clinical progressions. Progressive disease (PD) was defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. Also, the sum must also demonstrate an absolute increase of at least 5 millimeter (mm). The appearance of one or more new lesions is also considered progression.

Time frame:
Randomization to Progressive Disease (Up To 58.78 Months)
Reported as:
Median · months
Time To Progressive Disease (TTPD)
months250 mg Gefitinib/500 mg Pemetrexed250 mg Gefitinib
Time To Progressive Disease (TTPD)16.23 (12.58 to 18.73)10.94 (9.66 to 13.83)
Statistical analysis
  • 250 mg Gefitinib/500 mg Pemetrexed vs 250 mg Gefitinib · Regression, Cox · p = 0.005 (1 sided.) · Hazard ratio (hr): 0.64 · 95% CI 0.46 to 0.90Adjusted for gender, performance status, previous adjuvant /neoadjuvant treatment, age, smoking history, mutation type, and country.
SecondaryOverall Survival (OS)

OS is defined as the time from randomization to the date of death from any cause. Survival time is censored at the date of last contact for participants who are still alive or lost to follow up.

Time frame:
Randomization to Date of Death Due to Any Cause (Up To 67.12 Months)
Reported as:
Median · Months
Overall Survival (OS)
Months250 mg Gefitinib/500 mg Pemetrexed250 mg Gefitinib
Overall Survival (OS)43.43 (33.35 to 50.83)36.76 (26.74 to 42.64)
Statistical analysis
  • 250 mg Gefitinib/500 mg Pemetrexed vs 250 mg Gefitinib · Regression, Cox · p = 0.105 (1 sided.) · Hazard ratio (hr): 0.77 · 95% CI 0.51 to 1.16Adjusted for gender, performance status, previous adjuvant /neoadjuvant treatment, age, smoking history, mutation type, and country.
SecondaryPercentage of Participants Achieving Complete Response (CR) or Partial Response (PR) (Overall Response Rate [ORR])

ORR is the best response of complete response (CR) or partial response (PR) as classified by the investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). Complete Response (CR) is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Tumor marker results must have normalized. Partial Response (PR) is defined at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters.

Time frame:
Randomization to Progressive Disease (Up to 57.36 Months)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) (Overall Response Rate [ORR])
percentage of participants250 mg Gefitinib/500 mg Pemetrexed250 mg Gefitinib
Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) (Overall Response Rate [ORR])80.273.8
SecondaryPercentage of Participants With CR, PR, and Stable Disease (SD) (Disease Control Rate [DCR])

Disease control rate is the percentage of participants with a confirmed CR, PR or SD as classified by the investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST version 1.1) criteria. CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Tumor marker results must have normalized. PR is defined at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters. SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

Time frame:
Randomization to Progressive Disease (Up To 57.36 Months)
Reported as:
Number · percentage of participants
Percentage of Participants With CR, PR, and Stable Disease (SD) (Disease Control Rate [DCR])
percentage of participants250 mg Gefitinib/500 mg Pemetrexed250 mg Gefitinib
Percentage of Participants With CR, PR, and Stable Disease (SD) (Disease Control Rate [DCR])92.993.8
SecondaryDuration of Response (DoR)

DoR was defined as the time from the date of the first CR or PR to the first date of Progressive Disease (PD) ( RECIST 1.1 Criteria) or death from any cause.CR is the disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \<10 mm.Tumor marker results must have normalized. PR is defined as at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters. PD was defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. Also,the sum must also demonstrate an absolute increase of at least 5 mm.The appearance of one or more new lesions is also considered progression. Participants not known to have died or to have had progression of disease as of the data-inclusion cut-off date for a particular analysis,duration of tumor response was censored at the date of the participants last tumor assessment prior to that cut-off date.

Time frame:
First Observation of CR or PR to Progressive Disease or Death Due to Any Cause (Up To 57.36 Months)
Reported as:
Median · Months
Duration of Response (DoR)
Months250 mg Gefitinib/500 mg Pemetrexed250 mg Gefitinib
Duration of Response (DoR)15.44 (10.87 to 17.71)11.30 (8.31 to 16.36)
SecondaryTime to Worsening of Symptom (TWS) as Per Lung Cancer Symptom Scale (LCSS)

TWS was the elapsed time from the date of randomization to the first date of worsening in any one of the 6 LCSS symptoms. The LCSS (patient and observer) were administered at baseline and at the end of each 21-day cycle, until disease progression, and at short-term follow-up. Content for the patient version -collected using a visual analog scale (VAS) anchored at 0 and 100, respectively representing the best and worst outcome- included 6 disease-specific measures: (appetite, fatigue, cough, dyspnea, hemoptysis and pain) and 3 summary consequences of lung cancer (overall symptom burden, diminished normal activities, and lowered quality-of-life).The observer version included only the 6 disease-specific measures and the responses were collected using a 5-point ordinal scale that was reverse coded with 0 and 100 respectively representing the worst and best outcome.TWS was censored at the date of the last LCSS assessment for participants who were not known to have LCSS worsening.

Time frame:
Baseline to Progressive Disease (Up To 50 Months )
Reported as:
Median · months
Time to Worsening of Symptom (TWS) as Per Lung Cancer Symptom Scale (LCSS)
months250 mg Gefitinib/500 mg Pemetrexed250 mg Gefitinib
a. Loss of Appetite (Patient-rated)5.39 (3.68 to 12.29)7.66 (3.52 to NA)
b. Fatigue (Patient-rated)8.51 (4.47 to 25.46)7.66 (2.79 to NA)
c. Cough (Patient-rated)18.76 (8.15 to NA)NA (11.79 to NA)
d. Dyspnea (Patient-rated)18.76 (11.66 to NA)24.87 (9.07 to NA)
e. Hemoptysis (Patient-rated)NA (21.06 to NA)NA (10.68 to NA)
f. Pain (Patient-rated)34.83 (16.03 to NA)NA (15.47 to NA)
g. Overall Symptoms (Patient-rated)10.12 (5.85 to 21.55)30.46 (8.34 to NA)
h. Interference (Patient-rated)5.72 (3.58 to 12.58)24.71 (9.72 to NA)
i. Quality of Life (Patient-rated)13.40 (4.24 to 34.83)10.61 (5.29 to NA)
j. Loss of Appetite (Observer-rated)8.61 (5.36 to 18.73)34.10 (11.14 to NA)
k. Fatigue (Observer-rated)7.52 (5.09 to 13.93)12.98 (4.17 to NA)
l. Cough (Observer-rated)41.92 (19.68 to NA)NA (23.26 to NA)
m. Dyspnea (Observer-rated)NA (15.31 to NA)NA (19.32 to NA)
n. Hemoptysis (Observer-rated)NA (26.74 to NA)NA (NA to NA)
o. Pain (Observer-rated)34.83 (19.65 to NA)10.51 (4.90 to 35.88)
Statistical analysis
  • 250 mg Gefitinib/500 mg Pemetrexed vs 250 mg Gefitinib · Hazard ratio (hr): 1.17 · 95% CI 0.77 to 1.78
  • 250 mg Gefitinib/500 mg Pemetrexed vs 250 mg Gefitinib · Hazard ratio (hr): 0.92 · 95% CI 0.60 to 1.42
  • 250 mg Gefitinib/500 mg Pemetrexed vs 250 mg Gefitinib · Hazard ratio (hr): 1.39 · 95% CI 0.84 to 2.30
  • 250 mg Gefitinib/500 mg Pemetrexed vs 250 mg Gefitinib · Hazard ratio (hr): 1.06 · 95% CI 0.65 to 1.71
  • 250 mg Gefitinib/500 mg Pemetrexed vs 250 mg Gefitinib · Hazard ratio (hr): 0.57 · 95% CI 0.32 to 1.02
  • 250 mg Gefitinib/500 mg Pemetrexed vs 250 mg Gefitinib · Hazard ratio (hr): 1.11 · 95% CI 0.64 to 1.91
  • 250 mg Gefitinib/500 mg Pemetrexed vs 250 mg Gefitinib · Hazard ratio (hr): 1.10 · 95% CI 0.68 to 1.77
  • 250 mg Gefitinib/500 mg Pemetrexed vs 250 mg Gefitinib · Hazard ratio (hr): 1.38 · 95% CI 0.88 to 2.17
  • 250 mg Gefitinib/500 mg Pemetrexed vs 250 mg Gefitinib · Hazard ratio (hr): 1.12 · 95% CI 0.72 to 1.74
  • 250 mg Gefitinib/500 mg Pemetrexed vs 250 mg Gefitinib · Hazard ratio (hr): 1.56 · 95% CI 0.97 to 2.49
  • 250 mg Gefitinib/500 mg Pemetrexed vs 250 mg Gefitinib · Hazard ratio (hr): 1.26 · 95% CI 0.82 to 1.93
  • 250 mg Gefitinib/500 mg Pemetrexed vs 250 mg Gefitinib · Hazard ratio (hr): 1.24 · 95% CI 0.72 to 2.15
  • 250 mg Gefitinib/500 mg Pemetrexed vs 250 mg Gefitinib · Hazard ratio (hr): 1.09 · 95% CI 0.64 to 1.83
  • 250 mg Gefitinib/500 mg Pemetrexed vs 250 mg Gefitinib · Hazard ratio (hr): 1.32 · 95% CI 0.60 to 2.91
  • 250 mg Gefitinib/500 mg Pemetrexed vs 250 mg Gefitinib · Hazard ratio (hr): 0.65 · 95% CI 0.41 to 1.03

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
250 mg Gefitinib/500 mg Pemetrexed—31/126 (24.6%)123/126 (97.6%)
250 mg Gefitinib—9/65 (13.8%)63/65 (96.9%)
Most frequent serious events
Showing 10 of 43
Most frequent serious events
Event250 mg Gefitinib/500 mg Pemetrexed250 mg Gefitinib
IleusGastrointestinal disorders4/1260/65
Pleural effusionRespiratory, thoracic and mediastinal disorders0/1262/65
Lung infectionInfections and infestations3/1261/65
Urinary tract infectionInfections and infestations3/1260/65
Febrile neutropeniaBlood and lymphatic system disorders2/1260/65
CataractEye disorders2/1260/65
Gastritis erosiveGastrointestinal disorders2/1260/65
PneumoniaInfections and infestations2/1260/65
Spinal compression fractureInjury, poisoning and procedural complications2/1260/65
Subdural haematomaInjury, poisoning and procedural complications2/1260/65
Most frequent other events
Showing 10 of 379
Most frequent other events
Event250 mg Gefitinib/500 mg Pemetrexed250 mg Gefitinib
DiarrhoeaGastrointestinal disorders69/12635/65
Aspartate aminotransferase increasedInvestigations57/12624/65
Dermatitis acneiformSkin and subcutaneous tissue disorders49/12629/65
Alanine aminotransferase increasedInvestigations52/12625/65
Decreased appetiteMetabolism and nutrition disorders49/12617/65
StomatitisGastrointestinal disorders47/12615/65
Dry skinSkin and subcutaneous tissue disorders33/12624/65
FatigueGeneral disorders45/12615/65
PruritusSkin and subcutaneous tissue disorders44/12622/65
NauseaGastrointestinal disorders41/1269/65

Baseline characteristics

All participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)250 mg Gefitinib/500 mg Pemetrexed250 mg GefitinibTotal
Mean62.11 ± 9.3660.94 ± 9.4561.71 ± 9.38
Sex: Female, Male
Sex: Female, Male(Participants)250 mg Gefitinib/500 mg Pemetrexed250 mg GefitinibTotal
Female8241123
Male442468
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)250 mg Gefitinib/500 mg Pemetrexed250 mg GefitinibTotal
Hispanic or Latino000
Not Hispanic or Latino12665191
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)250 mg Gefitinib/500 mg Pemetrexed250 mg GefitinibTotal
American Indian or Alaska Native000
Asian12665191
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)250 mg Gefitinib/500 mg Pemetrexed250 mg GefitinibTotal
China331952
Japan421557
Taiwan281341
Korea, Republic of231841
08

Study locations

25 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Beijing, 100036, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Changchun, 130012, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Changsha, 410013, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Guang Zhou, 510120, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sichuan, 610041, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Aichi, 464-8681, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chiba, 277 8577, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hyogo, 650-0046, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kanagawa, 228-0329, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Okayama, 710-8602, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Osaka, 589-8511, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Shizuoka, 411-8777, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tokyo, 104-0045, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Yamaguchi, 755-0241, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Cheong Ju-City, 361-711, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Incheon, 405-760, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Seoul, 135 720, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Suwon-City, 442-723, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Jhonghe City, 235, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kaohsiung, 824, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Keelung, 204, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kuei Shan Hsiang, 33305, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Niao Sung Hsiang, 833, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Taichung, 40705, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Taipei, 100, Taiwan
09

References and documents

Publications

  • Cheng Y, Murakami H, Yang PC, He J, Nakagawa K, Kang JH, Kim JH, Wang X, Enatsu S, Puri T, Orlando M, Yang JC. Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations. J Clin Oncol. 2016 Sep 20;34(27):3258-66. doi: 10.1200/JCO.2016.66.9218. Epub 2016 Aug 9. PubMed 27507876 ↗

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2012, a primary completion of Apr 2015 and a completion of Nov 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2016, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2011
First posted
Nov 10, 2011
Start
Feb 2012
Primary completionActual
Apr 2015
CompletionActual
Nov 2017
Results first posted
Apr 28, 2016
Last update
Sep 10, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01469000
Responsible party
Sponsor
First posted
Nov 10, 2011
Start date
Feb 2012
Primary completion
Apr 2015
Completion
Nov 2017
Results posted
Apr 28, 2016
Last update
Sep 10, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pemetrexed

Start the discussion